Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

3DM Inc.

This article was originally published in Start Up

Executive Summary

The field of tissue engineering has long sought a synthetic version of the extracellular matrix and 3DM Inc. may just have found the ideal synthetic nano-scaffold to fill the void. The company's founders-many of whom come from the Massachusetts Institute of Technology (MIT)-make up a "Who's Who" of biomaterials and tissue engineering.

You may also be interested in...



Healionics Corp.

Device manufacturers looking to bolster the biocompatibility of their products can now turn to Healionics, a supplier of biomaterial scaffolds designed to improve the biointegration of percutaneous or fully implanted medical devices. The company's STAR technology is a synthetic, three-dimensional matrix, similar to a thin, porous sponge. Because this biomaterial has been precisely engineered with uniform pore sizes to the approximate size of a single cell, the company says that living tissue and new blood vessels actually grow and weave into these pores.

Breaking the Surgical Adhesion Barrier

Post-surgical adhesions occur almost any time a surgeon opens up a body cavity; in intra-abdominal surgery, for example, they form 85-90% of the time. But after a decade of trying, the medical device industry has only two adhesion prevention products to show for its efforts, and both products have drawbacks that have limited their market penetration. A new generation of companies--Confluent Surgical, Angiotech Pharmaceuticals, FzioMed, Sentrx Surgical, Afmedica, Kytogenics Pharmaceuticals, and ARC Pharmaceuticals, hope to profit from years of learning in the field to get new and improved products into the hands of surgeons .

Convergence and Complexity in Cardiac Regeneration

In heart failure, companies with expertise in gene or cell biology, or percutaneous delivery devices, see the first application where regenerative medicine could finally realize its promise. The enormous patient population, the high mortality of the disease, and the economics of treating it today provide a multi-billion dollar opportunity for which it's worth braving the complexity of cell therapy for tissue repair. Indeed, first-generation autologous heart cell therapies involve many different types of expertise resident in companies with different mindsets. Unknowns dog every component of the therapies on the level of basic biology. Still to be worked out: the right cell types; the optimal delivery route and device; when and at what dose cells should be administered, and in combination with which genes or drugs. Nevertheless, the great need in heart failure keeps companies dedicated to cardiac regeneration therapies. And as the cell therapy developers reveal new discoveries about the innate regenerative powers of the heart, drug developers are starting to move in, promising a much simpler approach than the combination products presently in the works.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel